ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Choroid Plexus Fibroblast-ILC2 Niche Promotes Adult Hippocampal Neurogenesis after Traumatic Brain Injury.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Meningeal macrophages regulate fibroblasts to influence meningeal lymphatic function following traumatic brain injury.Theranostics · 2026Article
- Choroid Plexus Fibroblast-ILC2 Niche Promotes Adult Hippocampal Neurogenesis after Traumatic Brain Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Mounting evidence has indicated that immune signals originating from the brain's border tissues will exert a profound influence on brain parenchyma neural cells. However, the structural component alterations and immune cell infiltration characteristics of choroid plexus (ChP) following traumatic brain injury (TBI) remain incompletely understood. Here, using single-cell RNA sequencing and histological analysis, the accumulation of group 2 innate lymphoid cell (ILC2) in the ChP stroma post-TBI is identified. Intracerebroventricular adoptive transfer of ILC2 is further indicated to exhibit a tendency to colonize the ChP and significantly alleviate pathogenic immune infiltration during the acute phase of TBI, as well as maintain hippocampal integrity during the chronic phase. Sensory-motor function and memory impairments in TBI mice are also improved under ILC2 treatment. Mechanistically, ILC2 is induced by ChP fibroblasts derived IL33 and anchored to stroma fibroblasts via the VCAM-1/Integrin α4β7 pathway. Furthermore, single-nucleus RNA sequencing of the hippocampus reveals that ILC2-derived AREG promotes the initiation of neurogenesis by interacting with EGFR on early-stage neurogenic cells. Overall, these findings highlight that ChP-resident ILC2, through optimizing the immune microenvironment and promoting neurogenesis after TBI, may represent a potential therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.